Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline
Aptevo Therapeutics Inc APVO
$4.11
▼ -0.48%
($-0.02)
🧊 52W Low
⬇️ Below Yest. Low
🎈 Low Float
🗓️ Earnings Next Week
Open
$4.07
Prev Close
$4.13
Day Range
$4.07 – $4.11
52W Range
$3.68 – $52.72
Market Cap
$5.12M
Beta
1.69
EPS (TTM)
$-197.29
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-07-20 |
| Shares Out. | 1,250,000 |
| Website | aptevotherapeutics.com/ ↗ |
| Phone | 12068380500 |
| Employees | 33 |
| Net Income | -$6.7M |
| Total Assets | $19.9M |
| Total Liabilities | $8.3M |
| Equity | $11.6M |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Aptevo Therapeutics Inc is a publicly traded company under the ticker symbol APVO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)